Affinia Therapeutics Inc. (AFTX)
| Market Cap | n/a |
| Revenue (ttm) | 8.06M |
| Net Income (ttm) | -39.77M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AFTX
Affinia Therapeutics is a preclinical stage company pioneering a new class of rationally designed gene therapies with potentially curative benefit in patients with both rare and prevalent devastating diseases. We created our proprietary Affinia Rationally-designed Therapies (ART) platform to develop these novel therapies, focusing on the three key components of a gene therapy: capsids, which are the outer shells of a virus used to deliver the genetic code to tissues to treat a disease; promoters, which control how the cells read the genetic cod... [Read more]
Financial Performance
Financial StatementsNews
Gene therapy biotech Affinia Therapeutics files for a $100 million IPO
Affinia Therapeutics, a preclinical biotech developing novel gene therapies for rare diseases and cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Affinia Therapeutics IPO Registration Document (S-1)
Affinia Therapeutics has filed to go public with an IPO on the NASDAQ.
Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs
Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to...